China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data
admin 10th April 2020 Uncategorised 0In the global race to develop an effective vaccine to protect people against the novel coronavirus, China’s CanSino Bio has leapt ahead. The biotech has started enrollment activities of a phase 2 trial testing its recombinant shot, Ad5-nCoV, in healthy volunteers in the city of Wuhan.
More: China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data
Source: fierce